CBS 2019
CBSMD教育中心
中 文

Congestive Heart Failure

Abstract

Recommended Article

Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights From EMPEROR-Reduced Evaluation and Management of Right-Sided Heart Failure: A Scientific Statement From the American Heart Association Cardiac Resynchronization Therapy and Ventricular Tachyarrhythmia Burden Nocturnal thoracic volume overload and post-discharge outcomes in patients hospitalized for acute heart failure Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status - Results from the EMPEROR-Reduced Trial When and how to use SGLT2 inhibitors in patients with HFrEF or chronic kidney disease The pyruvate-lactate axis modulates cardiac hypertrophy and heart failure Dapagliflozin for treating chronic heart failure with reduced ejection fraction

Guideline2017 Aug 8;70(6):776-803

JOURNAL:J Am Coll Cardiol. Article Link

2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America

Yancy CW, Jessup M, Bozkurt B et al. Keywords: ACC/AHA Clinical Practice Guidelines; angioedema; angiotensin receptor blockers; angiotensin receptor-neprilysin inhibitor; angiotensin-converting enzyme inhibitors; beta blockers; ferric carboxymaltose; focused update; heart failure; hypertension; iron deficiency; ivabradine; natriuretic peptide biomarker; natriuretic peptides; sleep apnea

Full Text PDF